Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-CEED: azetukalner versus placebo in bipolar depression
2025-522775-29-00Phase 3Suspended
- Sponsor
- Xenon Pharmaceuticals
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Azetukalner with Placebo (2 arms). Primary endpoint: Change from baseline in MADRS total score at Week 6. Started Jun 2026; status: suspended.
02
Drugs
azetukalner
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2025-522775-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522775-29-00.